We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Gives Green Light to Merck’s Zepatier for HCV Genotypes 1 and 4
FDA Gives Green Light to Merck’s Zepatier for HCV Genotypes 1 and 4
The FDA on Thursday blessed Merck’s Zepatier, a combination of elbasvir and grazoprevir, with or without ribavirin, for treatment of chronic hepatitis C virus genotypes 1 and 4.